Literature DB >> 16148728

Giant cell arteritis: laboratory tests at the time of diagnosis in a series of 240 patients.

Miguel A Gonzalez-Gay1, Maria J Lopez-Diaz, Sonia Barros, Carlos Garcia-Porrua, Amalia Sanchez-Andrade, Jose Paz-Carreira, Javier Martin, Javier Llorca.   

Abstract

The outcome of a patient with giant cell arteritis (GCA) is closely related to the development of severe ischemic manifestations. In the current study we analyzed the implications of routine laboratory tests obtained at the time of diagnosis in the clinical spectrum of a series of 240 consecutive patients with biopsy-proven GCA at the single hospital for a defined population. We also examined whether the laboratory markers of inflammation may be predictors of severe ischemic manifestations (visual ischemic events, cerebrovascular accidents, jaw claudication, or large-artery stenosis of the extremities of recent onset), and their potential correlation. Anemia (hemoglobin <12 g/dL) was observed in 131 (54.6%) and thrombocytosis in 117 (48.8%) patients. Sixty-eight (28.3%) patients had leukocytosis. The percentage of patients showing a significant increase of alkaline phosphatase and hypoalbuminemia was similar (25% and 27.8%, respectively). The mean values of erythrocyte sedimentation rate (ESR) and C-reactive protein were 93 +/- 23 mm/h and 94 +/- 63 mg/L, respectively. A strong correlation among most laboratory markers of inflammation was observed. Anemia was more commonly observed in patients without severe ischemic manifestations (61.5% versus 48.9% in those with severe ischemic manifestation; p = 0.05) and in patients with constitutional syndrome or fever (p < 0.001). Patients with ESR greater than 100 mm/h exhibited more commonly constitutional syndrome (p < 0.001) and had a statistically significant reduction in the incidence of visual ischemic events (p < 0.025). Only 7 (22.6%) of the 31 patients who suffered permanent visual loss had an ESR at the time of disease diagnosis greater than 100 mm/h. However, in a multivariate logistic regression analysis, only anemia was found to be a negative predictor for the development of severe ischemic manifestations of GCA (odds ratio, 0.53; 95% confidence intervals, 0.30-0.94; p = 0.03). In conclusion, our results suggest that some laboratory markers of inflammation, in particular the presence of anemia, may negatively predict the risk of severe ischemic complications in GCA patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16148728     DOI: 10.1097/01.md.0000180043.19285.54

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


  29 in total

Review 1.  Giant cell arteritis and polymyalgia rheumatica: pathophysiology and management.

Authors:  Miguel A Gonzalez-Gay; Carlos Garcia-Porrua; Jose A Miranda-Filloy; Javier Martin
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

Review 2.  Giant cell arteritis: diagnosis and therapeutic management.

Authors:  Miguel A Gonzalez-Gay; Carlos Garcia-Porrua; Jose A Miranda-Filloy
Journal:  Curr Rheumatol Rep       Date:  2006-08       Impact factor: 4.592

Review 3.  Polymyalgia rheumatica and giant cell arteritis in older patients: diagnosis and pharmacological management.

Authors:  Jean Schmidt; Kenneth J Warrington
Journal:  Drugs Aging       Date:  2011-08-01       Impact factor: 3.923

4.  68-year-old woman with confusion.

Authors:  Mohammed K Saghir; Kathrin Czarnecki; Murali K Duggirala
Journal:  Mayo Clin Proc       Date:  2009-08       Impact factor: 7.616

Review 5.  Diagnosis and treatment of giant cell arteritis.

Authors:  Fabrizio Cantini; Laura Niccoli; Carlotta Nannini; Michele Bertoni; Carlo Salvarani
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

6.  Ocular pulse amplitude as a diagnostic adjunct in giant cell arteritis.

Authors:  P B Knecht; L M Bachmann; M A Thiel; K Landau; C Kaufmann
Journal:  Eye (Lond)       Date:  2015-06-19       Impact factor: 3.775

7.  [New biomarkers for large vessel vasculitis and spondyloarthropathies].

Authors:  N T Baerlecken
Journal:  Z Rheumatol       Date:  2017-08       Impact factor: 1.372

Review 8.  Clinical diagnosis and management of large vessel vasculitis: giant cell arteritis.

Authors:  Soumya Chatterjee; Scott D Flamm; Carmela D Tan; E Rene Rodriguez
Journal:  Curr Cardiol Rep       Date:  2014-07       Impact factor: 2.931

9.  Autoimmunity and the risk of myeloproliferative neoplasms.

Authors:  Sigurdur Y Kristinsson; Ola Landgren; Jan Samuelsson; Magnus Björkholm; Lynn R Goldin
Journal:  Haematologica       Date:  2010-01-06       Impact factor: 9.941

10.  Association between IL-18 gene polymorphisms and biopsy-proven giant cell arteritis.

Authors:  Rogelio J Palomino-Morales; Tomas R Vazquez-Rodriguez; Orlando Torres; Inmaculada C Morado; Santos Castañeda; Jose A Miranda-Filloy; Jose L Callejas-Rubio; Benjamin Fernandez-Gutierrez; Miguel A Gonzalez-Gay; Javier Martin
Journal:  Arthritis Res Ther       Date:  2010-03-23       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.